Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic

Welt, Frederick G.P.; Shah, Pinak; Aronow, Herbert D.; Bortnick, Anna E.; Henry, Timothy D.; Sherwood, Matthew W.; Young, Michael N.; Davidson, Laura; Kadavath, Sabeeda; Mahmud, Ehtisham; Kirtane, Ajay J.

doi:10.1016/j.jacc.2020.03.021

Cited by 369 publications

(400 citation statements)

References 2 publications

Supporting

Mentioning

377

Contrasting

Unclassified

Order By: Relevance

“…To minimize the risk of exposure to COVID-19 and to conserve PPE, the treatment team should be limited to essential personnel and should not include trainees. We agree with recommendations from the ACC Interventional Council and SCAI that those who scrub for procedures should don PPE suitable for airborne precautions, including an N95 respirator and a face shield, given the risk of emergent intubation and need for cardiopulmonary resuscitation (20). Patients with unstable, deteriorating respiratory conditions should be intubated prior to transfer to minimize the risk of intubation in the CCL.…”

Section: Minimizing the Risk Of Covid-19 Exposure During Structural Hmentioning

confidence: 56%

Restructuring Structural Heart Disease Practice During the COVID-19 Pandemic

Chung

Nazif

Wolbinski

et al. 2020

Journal of the American College of Cardiology

View full text Add to dashboard Cite

Patients with structural heart disease (SHD) are at increased risk of adverse outcomes from the coronavirus disease 19 (COVID-19) due to advanced age and comorbidity. In the midst of a global pandemic of a novel infectious disease, reality-based considerations comprise an important starting point for formulating clinical management pathways. The aim of these "crisisdriven" recommendations is (1) to ensure appropriate and timely treatment of SHD patients, (2) to minimize the risk of COVID-19 exposure to patients and healthcare workers, and (3) to limit resource utilization under conditions of constraint. While the degree of disruption to usual practice will vary across the United States and elsewhere, we hope that early experiences from a Heart Team operating in the current global epicenter of COVID-19 may prove useful for others adapting their practice in advance of local surges of COVID-19.

show abstract

Section: Minimizing the Risk Of Covid-19 Exposure During Structural Hmentioning

confidence: 56%

Restructuring Structural Heart Disease Practice During the COVID-19 Pandemic

Chung

Nazif

Wolbinski

et al. 2020

Journal of the American College of Cardiology

View full text Add to dashboard Cite

show abstract

“…Prior to intervention, efforts should be made to distinguish non-specific myocardial injury, myocarditis, and true plaque rupture presentations (104). A low threshold to use transthoracic echocardiography to identify wall motion abnormalities should be considered prior to catheterization laboratory activation.…”

Section: Covid-19 and Interventional Therapies For Acsmentioning

confidence: 99%

“…Use of telemedicine in place of in-person office visits is a strategy to minimize physical exposure. Further details have been discussed elsewhere (5,104).…”

Section: Impact Of Covid-19 On Healthcare Workers and Health Systemsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Bikdeli

Madhavan

Jiménez

et al. 2020

Journal of the American College of Cardiology

2,614

2,886

View full text Add to dashboard Cite

Patients with acute respiratory distress syndrome due to infection with the novel coronavirus SARS-COV2 are currently considered at high risk of developing thromboembolic complications in both venous and arterial vessels. The use of anticoagulants for preventive or curative purposes should be considered to reduce the risk of thromboembolic events. We report a case of a patient with severe COVID-19 acute respiratory distress syndrome who consecutively developed a right femoral deep vein thrombosis related to the femoral central line and acute ischemia of the left upper limb related to a radial arterial line. He was under a therapeutic dose of low molecular weight heparin twice a day three days before. The femoral vein was free of thrombosis while the central line was placed under a duplex ultrasound. Thromboembolic events can occur in patients with severe COVID-19 despite therapeutic anticoagulants. Close monitoring of vascular access with duplex ultrasound may be required.

show abstract

“…Therefore, it is plausible that ACS will also be an important cause of acute cardiac injury in patients with COVID-19. Accordingly, international societies have devised pathways and protocols to effectively treat COVID-19 patients with ACS, including appropriate and timely use of resources to ensure the best outcome for the patient while also maintaining provider safety (99).…”

Section: Acute Coronary Syndromementioning

confidence: 99%

COVID-19 for the Cardiologist

Atri

Siddiqi

Lang

et al. 2020

JACC: Basic to Translational Science

252

123

View full text Add to dashboard Cite

Highlights-Severe acute respiratory virus-2 (SARS-CoV2), the infection responsible for coronavirus disease-2019 (COVID-19), has spread globally leading to a devastating loss of life. In a few short months, the clinical and scientific communities have rallied to rapidly evolve our understanding of the mechanism(s) of disease and potential therapeutics. -This review discusses the current understanding of the basis virology of SARS-CoV2 and the epidemiology, clinical manifestations, including cardiovascular, and mortality of COVID-19. A detailed review of the viral life cycle and putative mechanism(s) of injury frames the discussion of possible preventative and therapeutic strategies. -The ongoing, unprecedented collective effort will, without a doubt, advance our ability to prevent the spread and optimally care for patients suffering from COVID-19. SummaryThe coronavirus disease-2019 (COVID-19), a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), has reached pandemic status. As it spreads across the world, it has overwhelmed healthcare systems, strangled the global economy and led to a devastating loss of life. Widespread efforts from regulators, clinicians and scientists are driving a rapid expansion of knowledge of the SARS-CoV2 virus and the COVID-19 disease.We review the most current data with a focus on our basic understanding of the mechanism(s) of disease and translation to the clinical syndrome and potential therapeutics. We discuss the basic virology, epidemiology, clinical manifestation, multi-organ consequences, and outcomes. With a focus on cardiovascular complications, we propose several mechanisms of injury. The virology and potential mechanism of injury form the basis for a discussion of potential disease-modifying therapies.

show abstract

Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic

Cited by 369 publications

References 2 publications

Restructuring Structural Heart Disease Practice During the COVID-19 Pandemic

Restructuring Structural Heart Disease Practice During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

COVID-19 for the Cardiologist

Contact Info

Product

Resources

About